What Population Health Partners does

Population Health Partners (PHP), L.P. is a private investment limited partnership focused on healthcare and life sciences. Founded around 2020-2022 and headquartered in Bernardsville, New Jersey, the firm operates with a lean team of 1-10 employees and deploys capital primarily into healthcare companies, with a thematic tilt toward digital health and precision medicine. The firm's leadership includes Clive Meanwell (Executive Chairman & Co-Founder), Whit Bernard (Managing Partner), and Tom Denwood (Chief Digital Officer); Foresite Capital provided anchor capital to PHP in 2023.

PHP's portfolio spans healthcare subsectors, including precision health (Corsera Health, $80M Series A co-led in January 2026), digital health engagement (dacadoo, strategic partnership December 2025), and biotech (Metsera, acquired by Pfizer for approximately $10 billion). The firm co-invests with established healthcare-specialist investors including Forbion and ARCH Venture Partners. Its strategic partnerships — such as the dacadoo relationship — combine capital deployment with operating support for portfolio companies.

The business model is that of a traditional private investment partnership: revenue is generated from management fees on committed/deployed capital and from carried interest on realized exits. PHP pursues a "capital plus partnerships" model, using co-investor networks and senior operating expertise to source, diligence, and support deals. The combination of a small operating footprint, a senior leadership bench with direct industry experience, and anchor backing from Foresite Capital positions PHP as a specialist healthcare investor rather than a generalist fund.

Name

Population Health Partners

Legal name

Population Health Partners, L.P.

Website

https://populationhp.com

Company type

Private

Founded year

2020

Operating status

Operating

Headcount range

1–10 employees

Short description

Population Health Partners is a private, healthcare-focused investment limited partnership that deploys capital into digital health and precision medicine companies and forms strategic partnerships with co-investors and operating platforms.

Ownership category

akta.pro rank

Product category

Healthcare Venture Capital and Growth Equity

NAICS

Health Care and Social Assistance (62)

akta.pro primary industry

Global Health Financing Mechanisms (HLAJAKAC)

akta.pro secondary industries

Health Research Funding Agencies (Public/Quasi-Public) (HLAJALAB), Global Health Research, Clinical Trials & Product Development Partnerships (PDPs) (HLAJAOAM)

Keywords

• Healthcare venture capital
• Life sciences investing
• Biotech growth equity
• Cardiovascular therapeutics investment
• Digital health partnerships

Headquarters

HQ city

San Francisco

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Others

Revenue model

1. Fund Management and Investment Advisory: Population Health Partners operates as an investment partnership managing capital for institutional and qualified investors. The firm generates returns through equity investments in healthcare portfolio companies, with revenue derived from carried interest on successful exits and management fees from fund operations. The firm participates in financing rounds alongside strategic co-investors to support portfolio company growth.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels1 record

Core offering

Population Health Partners is an investment partnership that deploys capital into healthcare-focused companies developing innovative therapeutics and digital health technologies. The firm co-leads growth-stage financing rounds (e.g., $80M Series A for Corsera Health) and pursues strategic partnerships (e.g., dacadoo) to support portfolio companies in cardiovascular, obesity, and AI-enabled health. Limited partnership interests are offered privately to qualified investors.

Differentiator

Problem solved

Functional benefit

Quantifiable outcome

• Co-led $80M Series A financing for Corsera Health, supporting Phase 1 clinical trial initiation for COR-1004 siRNA therapeutic targeting PCSK9
• +1 more outcomes

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

One partnership is on record.

• dacadoocoreStrategic or Co-development Partner · 17 December 2025Population Health Partners and dacadoo announced a strategic partnership to develop and deploy outcome-based digital health solutions. The collaboration aims to enhance health engagement through dacadoo's Digital Health Engagement Platform and Health Score technology, supporting next-generation digital health initiatives globally. The partnership focuses on prevention and disease management applications, providing integrated digital health engagement capabilities to the broader healthcare ecosystem.

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• MPM Capital: Healthcare-dedicated venture firm investing across oncology, cardiovascular, and rare disease therapeutics. Comparable thesis and stage focus to PHP.
• RA Capital Management: Healthcare-specialist long-only and crossover investor actively leading biotech Series A rounds. Directly comparable as a stage and thesis-aligned co-investor to PHP.
• Foresite Capital: Healthcare- and genomics-focused venture and growth investor; funded alongside PHP per leadership disclosures. Comparable healthcare-only mandate and Series A through growth focus.
• Forbion: European life sciences-focused venture capital firm that co-led the $80M Corsera Health Series A with PHP. Directly comparable as a late-stage biotech/healthcare investor with similar syndicate activity and stage focus.
• Versant Ventures: Healthcare-dedicated venture firm with therapeutic focus areas spanning cardiovascular and metabolic disease. Comparable as a stage-aligned healthcare-only investor.
• ARCH Venture Partners: Long-standing life sciences venture firm and documented PHP co-investor in Metsera (ultimately acquired by Pfizer). Highly comparable in deploying large biotech rounds and stage focus.
• Atlas Venture: Boston-based life sciences venture firm building biotechs from inception. Comparable in therapeutic stage focus and Series A co-lead activity around RNA and metabolic disease.

Emerging players

• Andreessen Horowitz Bio + Health: Crossover generalist VC with an active Bio + Health fund investing in digital health and biotech. Partial overlap with PHP, particularly around digital health/dacadoo-style engagements.

Broad incumbents

• OrbiMed: One of the largest dedicated healthcare investment firms globally, spanning venture, growth, and credit. Comparable as a healthcare-only investor though much broader in stage and instrument.
• NEA (New Enterprise Associates): Large generalist VC with a substantial healthcare/biotech practice. Overlaps with PHP in cardiovascular and digital health rounds, though it operates a much broader portfolio.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/populationhp

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds2 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments9 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Population Health Partners